Home Neuronal Signaling Dopamine Receptor antagonist Perphenazine

research use only

Perphenazine Dopamine Receptor antagonist

Cat.No.S4731

Perphenazine (Perphenazin, Trilafon, Etaperazine) is a phenothiazine derivative and a dopamine antagonist with antiemetic and antipsychotic properties.
Perphenazine Dopamine Receptor antagonist Chemical Structure

Chemical Structure

Molecular Weight: 403.97

Jump to

Quality Control

Batch: S473101 DMSO]74 mg/mL]false]Ethanol]74 mg/mL]false]Water]Insoluble]false Purity: 99.89%
99.89

Solubility

In vitro
Batch:

DMSO : 74 mg/mL (183.18 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Ethanol : 74 mg/mL

Water : Insoluble

Molarity Calculator

Mass Concentration Volume Molecular Weight
Dilution Calculator Molecular Weight Calculator

In vivo
Batch:

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg
g
μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO
%
% Tween 80
% ddH2O
% DMSO
+
%

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight 403.97 Formula

C21H26ClN3OS

 Storage (From the date of receipt)
CAS No. 58-39-9 Download SDF Storage of Stock Solutions

Synonyms Perphenazin, Trilafon, Etaperazine SMILES C1CN(CCN1CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)Cl)CCO

Read more about storage stability stock solution CAS number SMILES

Mechanism of Action

Targets/IC50/Ki
D1/D2 dopamine receptors
In vitro
Perphenazine is a relatively high potency phenothiazine that blocks dopamine 2 (D2) receptors predominantly but also may possess antagonist actions at histamine 1 (H1) and cholinergic M1 and alpha 1 adrenergic receptors in the vomiting center leading to reduced nausea and vomiting. This compound induces cell death and mitochondrial damage, also caspase-3 activation and a decrease in cellular ATP level. The cell death induced by this chemical is partially suppressed by antioxidant but not by pan-caspase inhibitor. This drug in concentration range from 0.0001 to 0.01 µM did not have any significant effect on melanocytes viability. The treatment of cells with the drug in higher concentrations results in the loss in cell viability in a concentration-dependent manner. The value of EC50 for this compound is 2.76 μM. It in concentrations of 1.0 and 3.0 µM also decreases the tyrosinase activity, as well as melanin content.
In vivo
Perphenazine is well absorbed after oral administration. The time to peak after oral administration is 1-3 hours with the time to peak of the metabolite 7-hydroxyperphenzaine 2-3 hours. This compound has a half-life elimination of 9-12 hours and its metabolite 7-hydroxyperphenazine of 10-19 hours. It has been used as a psychotropic drug for several decades in therapy of certain psychiatric disorders. In rat isolated heart, this chemical significantly prolongs the QT interval and triggers arrhythmias in considerable numbers both at the high concentration and at the therapeutical concentration. This proarrhythmogenic effect is observed even after repeated exposure to this compound.
References
  • [4] http://china.tandfonline.com/doi/abs/10.1080/19768354.2011.611256
  • [5] http://www.ptfarm.pl/pub/File/Acta_Poloniae/2016/nr%204/903.pdf

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2026-05-28)

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT04606264 COMPLETED
Perioperative Optimization
Jennifer Holder-Murray
 2023-05-15 PHASE3
NCT05762146 UNKNOWN
Ischemic Stroke, Acute
Maastricht University
 2022-09-05 PHASE2
NCT03510325 COMPLETED
Schizophrenia
Shanghai Mental Health Center
 2019-02-12 PHASE3
NCT04776499 COMPLETED
Drug Drug Interaction; Safety Issues
Maastricht University
 2021-03-18 PHASE1
NCT02431702 COMPLETED
Schizophrenia; Psychotic Disorders
Janssen Scientific Affairs, LLC
 2015-07-08 PHASE3
NCT02374567 TERMINATED
Dementia; Depression; Schizophrenia; Psychosomatic Disorders; Anxiety Disorders
Hannover Medical School
 2015-01 PHASE3

Read more about Clinical Trials

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Signaling Pathway Map